MONTGOMERY, Texas -- (Business Wire)
AngioSoma, Inc. (OTCQB:SOAN), previously known as First Titan Corp. (the
'Company', 'we', and 'our'), changed our corporate
name and focus to that of a clinical stage biopharmaceutical company
introducing an exciting new treatment for one of the world's most
insidious and pervasive diseases, peripheral artery disease ('PAD'). The
introduction of this new drug, Liprostin™, a liposomal controlled
release encapsulation of ProstaglandinE1 (PGE1), will greatly improve
the effectiveness of the drug and of current standard-of-care
treatments, especially when used with endovascular interventions such as
transluminal percutaneous angioplasty, stenting and atherectomy
interventions in the treatment of PAD. The Company's strengths include
our research team, flagship product Liprostin™, intellectual property
pipeline, and legacy oil & gas assets.
Our research team, headed by Chairman Emeritus Dr. David P.
Summers, PhD, are a multi-talented seasoned collection of applied
scientists and medical field specialists assembled to produce product
and market results – “this isn't their first rodeo!” Dr.
Summers’s biotechnical experience as both an engineer and biotechnical
scientist bringing intellectual property to market is extensive,
spanning multiple decades. “Working with Dr. Summers is an absolute
pleasure!His long history of leading research teams from product
& technology conceptualization, through product development, and then to
product sales is amazing,” said Alex Blankenship, AngioSoma, Inc.'s
CEO.
Liprostin™, our flagship product, is an FDA-approved product in a
new controlled delivery system, a sterically stable liposome that has
made our product, the well-known generic ProstaglandinE1 (PGE1), a brand
new drug with a brand new controlled delivery. The Liprostin™ market is
a very large multi-billion-dollar international market. There are many
derivative treatments such as diabetes, peripheral neuropathies, and
various vascular disorders that may be candidates for treatment once FDA
approval is obtained, and information amassed by our research team will
provide a continuous stream of intellectual property ('IP')
yielding future patent protection and future products.
Our intellectual property pipeline is large and has expired or
expiring patents providing a basis for new product development, patent
applications, and research, continually enlarging the pipeline and
future products even further.
The Company still owns assets in the oil & gas industry that
may provide independent shareholder value in the future. We have already
begun to explore various strategies to unlock this shareholder value
while not detracting from our current focus.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (http://www.angiosoma.com),
a Nevada corporation based in Montgomery, Texas, is a clinical stage
biotechnology company focused on improving the effectiveness of current
standard-of-care treatments, especially related to endovascular
interventions in the treatment of peripheral artery disease (“PAD”).
Our lead pharmaceutical product, Liprostin™, for the treatment of PAD,
has successfully completed FDA Phase I and three Phase II clinical
trials, and we are in discussions with several contract research
organizations ('CRO') for rapid completion of our U.S. Food and
Drug Administration ('FDA') approved protocol for Phase III with
submission of our new drug application ('NDA') for marketing in
the U.S. and its territories.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words “believes,” “expects,”
“anticipate” or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone’s past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160714005349/en/
Contacts:
AngioSoma, Inc.
Alex Blankenship, 832-781-8521
investors@AngioSoma.com
Source: AngioSoma, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.